Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Pharmaceutical Executive: July/August 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
An AI Pulse Checkalmost 2 years ago
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launchesalmost 2 years ago
A Promising Option: Exxuaalmost 2 years ago
Opening the Door: Omvohalmost 2 years ago
'Marked’ for Stardom?: Truqapalmost 2 years ago
Branching Off: Wegovyalmost 2 years ago
A Formidable First: Winrevairalmost 2 years ago
The Future of Launch Excellence is Generative AIalmost 2 years ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'almost 2 years ago
Big Bets, Bold StepsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5